Table 3.
Risk of acute pancreatitis and duration of current use of antidiabetic drugs (nested case-control analysis)
| Case subjects | Control subjects | OR (95% CI)* | |
|---|---|---|---|
| n | 419 | 5,000 | |
| Insulin | |||
| Nonuse† | 399 (95.2) | 4,650 (93.0) | 1 (referent) |
| Short duration (<1 year) | 7 (1.7) | 82 (1.6) | 0.41 (0.17–1.00) |
| Mid duration (1–3 years) | 5 (1.2) | 88 (1.8) | 0.34 (0.13–0.91) |
| Long duration (>3 years) | 7 (1.7) | 158 (3.2) | 0.30 (0.13–0.68) |
| Metformin | |||
| Nonuse† | 328 (78.3) | 4,261 (85.2) | 1 (referent) |
| Short duration (<1 year) | 26 (6.2) | 213 (4.3) | 0.88 (0.53–1.47) |
| Mid duration (1–3 years) | 31 (7.4) | 237 (4.7) | 0.93 (0.58–1.49) |
| Long duration (>3 years) | 18 (4.3) | 205 (4.1) | 0.50 (0.28–0.91) |
| Sulfonylureas | |||
| Nonuse† | 334 (79.7) | 4,460 (89.2) | 1 (referent) |
| Short duration (<1 year) | 13 (3.1) | 125 (2.5) | 0.81 (0.42–1.57) |
| Mid duration (1–3 years) | 25 (6.0) | 156 (3.1) | 1.20 (0.70–2.03) |
| Long duration (>3 years) | 31 (7.4) | 193 (3.9) | 1.66 (1.01–2.74) |
| Thiazolidinediones | |||
| Nonuse† | 396 (94.5) | 4,864 (97.3) | 1 (referent) |
| Short duration (<1 year) | 11 (2.6) | 57 (1.1) | 1.28 (0.61–2.68) |
| Mid duration (1–3 years) | 7 (1.7) | 46 (0.9) | 1.19 (0.49–2.90) |
| Long duration (>3 years) | 2 (0.5) | 14 (0.3) | 1.27 (0.23–6.89) |
| Other antidiabetic drugs | |||
| Nonuse† | 412 (98.3) | 4,962 (99.2) | 1 (referent) |
| Short duration (<1 year) | 1 (0.2) | 9 (0.2) | 1.24 (0.13–11.82) |
| Mid duration (1–3 years) | 1 (0.2) | 8 (0.2) | 0.94 (0.11–8.14) |
| Long duration (>3 years) | 2 (0.5) | 10 (0.2) | 1.85 (0.34–10.10) |
Data are n (%) unless otherwise indicated.
*Adjusted for all variables included in the table plus those in the fully adjusted model of Table 2.
†Baseline category.